Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.
Reg Anesth Pain Med. 2021 Aug;46(8):650-655. doi: 10.1136/rapm-2021-102479. Epub 2021 May 14.
The reported use of cannabis within surgical population is increasing. Cannabis use is potentially associated with increased harms and varied effects on pain control. These have important implications to perioperative care.
We conducted a retrospective cohort study comparing surgical patients reporting cannabis use preoperatively to control patients with no cannabis exposure, in a 1:2 ratio. To control for confounding, we used a propensity score-matched analysis to assess the adjusted association between cannabis use and study outcomes. Our primary outcome was a composite of (1) respiratory arrest or cardiac arrest, (2) intensive care admission, (3) stroke, (4) myocardial infarction and (5) mortality during this hospital stay. Secondarily, we assessed the effects on pain control, opioid usage, induction agent dose and nausea-vomiting.
Between January 2018 and March 2019, we captured 1818 patients consisting of cannabis users (606) and controls (1212). For propensity score-matched analyses, 524 cannabis patients were compared with 1152 control patients. No difference in the incidence of composite outcome was observed (OR 1.06, 95% CI 0.23 to 3.98). Although a higher incidence of arrhythmias (2.7% vs 1.6%) and decreased incidence of nausea-vomiting needing treatment (9.6% vs 12.6%) was observed with cannabis users vs controls, results were not statistically significant. No significant differences were observed with other secondary outcomes.
Our results do not demonstrate a convincing association between self-reported cannabis use and major surgical outcomes or pain management. Perioperative decisions should be made based on considerations of dose, duration, and indication.
报告称,手术人群中使用大麻的情况正在增加。大麻的使用可能会增加危害,并对疼痛控制产生不同的影响。这些对围手术期护理有重要影响。
我们进行了一项回顾性队列研究,将术前报告使用大麻的手术患者与无大麻暴露的对照患者按 1:2 的比例进行比较。为了控制混杂因素,我们使用倾向评分匹配分析来评估大麻使用与研究结果之间的调整关联。我们的主要结果是(1)呼吸骤停或心脏骤停,(2)入住重症监护病房,(3)中风,(4)心肌梗死和(5)在此住院期间的死亡率的综合指标。其次,我们评估了对疼痛控制、阿片类药物使用、诱导剂剂量和恶心呕吐的影响。
在 2018 年 1 月至 2019 年 3 月期间,我们共纳入了 1818 名患者,其中包括大麻使用者(606 名)和对照组(1212 名)。对于倾向评分匹配分析,将 524 名大麻患者与 1152 名对照患者进行了比较。复合结果的发生率没有差异(OR 1.06,95%CI 0.23 至 3.98)。尽管大麻使用者的心律失常发生率较高(2.7%比 1.6%),需要治疗的恶心呕吐发生率较低(9.6%比 12.6%),但差异无统计学意义。其他次要结果无显著差异。
我们的研究结果没有显示自我报告的大麻使用与主要手术结果或疼痛管理之间存在令人信服的关联。围手术期决策应根据剂量、持续时间和适应证来做出。